Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.20% year-on-year.
Undervalued
The company’s latest PE is -70.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 177.30M shares, decreasing 20.60% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 241.12K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.27.